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KEY POINTS:  
• Pathogen-inactivated platelets were noninferior in preventing bleeding only in intention-
to-treat analysis 
• In contrast to animal models, alloimmunization could not be prevented when using 
pathogen-inactivated platelets  
 
 
ABSTRACT 
Pathogen inactivation of platelet concentrates reduces the risk of blood-borne infections. 
However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We 
conducted a randomized noninferiority trial comparing the efficacy of pathogen inactivated 
platelets using riboflavin and ultraviolet B illumination technology (intervention) compared to 
standard plasma-stored platelets (control) for the prevention of bleeding in patients with 
hematologic malignancies and thrombocytopenia. The primary outcome parameter was the 
proportion of transfusion treatment periods in which the patient had grade 2 or higher 
bleeding as defined by World Health Organization (WHO) criteria. Between November 2010 
and April 2016, 469 unique patients were randomized to 567 transfusion treatment periods 
(283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in 
grade ≥ 2 bleeding in the intention-to-treat analysis: 51% of the transfusion treatment periods 
in the control arm and 54% in the intervention arm (95% CI -6 to 11, p-value for 
noninferiority 0.012). In the per-protocol analysis, however,  difference in grade ≥ 2 bleeding 
was 8%: 44% in the control arm and 52% in the intervention arm (95% CI -2 to 18, p-value 
for noninferiority 0.19). Transfusion increment parameters were about 50% lower in the 
intervention arm. There was no difference in the proportion of patients developing HLA class 
I alloantibodies. In conclusion, the noninferiority criterion for pathogen inactivated platelets 
was met in the intention-to-treat analysis. This finding was not demonstrated in the per 
protocol analysis. (The Netherlands National Trial Registry number: NTR2106).   
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INTRODUCTION 
There remains interest in development of pathogen inactivation techniques to complement the 
‘multi-layered prevention strategy’ to avert transfusion of blood products contaminated with 
currently known as well as unknown pathogens. The available pathogen inactivation systems 
for platelet concentrates inactivate a broad array of viruses, bacteria and parasites.1-4 
Moreover, these techniques have also shown sufficient white cell inactivation to prevent 
transfusion-associated graft versus host disease, and may also reduce the formation of Human 
Leukocyte Antigen (HLA) antibodies.5-7 If hemostatic efficacy of pathogen inactivated 
platelets is sufficiently maintained, these advantages could favor the consideration to 
implement pathogen inactivation technology. A meta-analysis of 12 randomized controlled 
trials concluded that transfusions with pathogen inactivated platelet concentrates resulted in 
reduced transfusion increment, without hemostatic consequences or differences in patient 
survival.8 In three of these trials riboflavin, also known as vitamin B2, with ultraviolet  
illumination (Mirasol pathogen inactivation technology; Terumo BCT, Lakewood, Colorado) 
was used to inactivate pathogens.9-11 Despite the available data, it is insufficiently known 
whether Mirasol treatment in platelet concentrates results in an equivalent hemostatic effect in 
this vulnerable population. As bleeding is considered to be the pivotal outcome for platelet 
transfusion trials, we conducted a non-inferiority randomized controlled trial comparing 
pathogen-inactivated platelet concentrates using the Mirasol technology with conventional 
untreated platelet concentrates, with percentage of transfusion treatment periods in which the 
patient has World Health Organization (WHO) grade ≥ 2 bleeding as primary outcome.12 As a 
secondary outcome we measured HLA antibody-formation to determine whether pathogen-
inactivated platelets are able to reduce alloimmunization in hemato-oncology patients.  
 
METHODS 
The PREPAReS study (Pathogen Reduction Evaluation and Predictive Analytical Rating 
Score) was designed as a randomized multicenter non-inferiority study using a parallel arm 
design with one-to-one randomization. The protocol was written by a steering committee and 
approved centrally and by site institutional review boards. The study met the criteria captured 
in the Declaration of Helsinki (6th revision, 2008) and Good Clinical Practice guidelines. All 
patients gave written informed consent before the randomization procedure or any other study 
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related proceeding. A detailed review of the protocol and methods used was published 
separately, and is only briefly summarized here.13 The study was conducted in three countries, 
in ten centers with hemato-oncology departments: 4 sites in the Netherlands, 5 in Canada and 
1 in Norway.  
 
Eligibility Criteria 
Hemato-oncology patients with chemotherapy-induced thrombocytopenia aged 18 years or 
older were eligible for inclusion in the study if they were expected to require at least two 
platelet transfusions during a transfusion treatment period (Figure S1 in the supplementary 
appendix). Patients presenting with a grade ≥ 2 bleeding before enrolment could only be 
enrolled with existing (i.e. not new) bruises, while patients with grade ≥ 2 bleeding at other 
organ systems than skin could be enrolled only 14 days after resolution of the bleed. Other 
exclusion criteria included: known immunological refractoriness to platelet transfusions; 
indications to use hyperconcentrated platelets; idiopathic thrombocytopenic purpura (ITP); 
pregnancy; microangiopathic thrombocytopenia; known allergy to riboflavin or its 
photoactive products. 
 
Stratification and Randomization 
Eligible patients were randomized to receive untreated plasma-stored platelet concentrates or 
pathogen-inactivated platelet concentrates using a centralized, web-based allocation tool. The 
random allocation schedule was prepared by a biostatistician not directly involved in the study 
using a 1:1 ratio and randomly-varying block sizes of two to six. Three stratification factors 
were applied: center, diagnosis (AML vs. non-AML) and treatment (transplant vs no-
transplant). Patients could be randomized more than once if they had subsequent hospital 
admissions, and the statistical analysis accounted for multiple randomizations per individual.  
 
Platelet products and transfusion policy 
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Platelet concentrates were all prepared from pooled buffy coats, resuspended in plasma, and 
leukoreduced by filtration.14 For pathogen inactivation, 35 ml (500 µM) riboflavin was added 
to the pooled leukoreduced product, and exposed to ultraviolet light (wavelength 280 – 315 
nm) for 5 – 10 minutes depending on the volume of the concentrate (total dose 6.2 J/ml) 
according to the manufacturer’s instructions. Platelet products were stored with gentle 
agitation at 20-24°C up to five days in Canada and for a maximum of seven days in the 
Netherlands and Norway.14 The products were composed of five buffy coats in the 
Netherlands, four buffy coats in Norway, and four or five buffy coats in Canada. The actual 
platelet content in the bags largely overlapped between the countries. 14 An automated culture 
system was used to detect bacterial contamination, and products were issued as ‘negative-to-
date’. Platelet concentrates were γ-irradiated as per local protocol. In both treatment arms, 
patients received platelet transfusions prophylactically (platelet count-related prophylaxis, 
trigger 10x109/L or intervention-related prophylaxis, trigger 50x109/L) or as treatment of 
bleeding, using national and hospital guidelines. Red cell concentrates and plasma were 
transfused based on local protocols for transfusion thresholds and at the treating physicians’ 
discretion.  
 
Outcomes and clinical assessments 
The primary study outcome was the proportion of transfusion treatment periods in which the 
patient had a bleeding complication WHO grade ≥ 2. The transfusion treatment period started 
at the time of the first platelet transfusion after randomization and ended maximally 6 weeks 
after the first platelet transfusion, or for one of the following reasons: patient was no longer 
thrombocytopenic (> 7 days without requiring a platelet transfusion), hospital discharge, 
death, or request by the patient to discontinue (Figure S1 in the supplementary appendix). 
Secondary outcomes were 1- and 24-hour corrected count increments, the frequency of 
transfusion failures (defined as 1-hour corrected count increment < 7.5 and 24-hour corrected 
count increments < 4.5), percentage of days within a transfusion treatment period with 
bleeding grade ≥ 2, incidence of adverse transfusion reactions, transfusion requirement of red 
cells and platelets, platelet transfusion interval, and the proportion of patients with HLA 
alloimmunization. Data collection was performed by trained research staff at each site, and 
data were entered into the ProMISe (Project Manager Internet Server) database from two 
central research locations in Canada and the Netherlands. Bleeding symptoms, as well as all 
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other clinical- and transfusion-related data were monitored daily on all study patients, starting 
at randomization, up to a maximum of 6 weeks after the first platelet transfusion, or end of 
thrombocytopenia as defined above. The study was not blinded, and bleeding assessments 
were performed by trained non-blinded research personnel. Hence, an adjudication process 
was used to assign each patients bleeding status to minimize bias. Bleeding adjudication, 
using the WHO bleeding scale, was done by three independent adjudicators blinded to the 
treatment allocation, in addition to the use of an automated algorithm.15 For HLA antibody 
detection, samples were collected weekly during hospitalization up till day 28, and a ‘late’ 
sample at approximately day 56, and tested in the Luminex assay (Luminex Corp., Austin, 
Texas, USA) for presence of single antigen HLA-antibodies at the Blood Systems Research 
Institute (San Francisco, California, USA).16 
 
Statistical analyses 
A pilot study showed that on average 50% of patients have bleeding ≥ grade 2 during their 
thrombocytopenic phase, confirming findings of earlier large platelet transfusion studies.17-19 
The study was designed as a non-inferiority trial to test the null-hypothesis that pathogen-
inactivated platelet concentrates are worse than control platelets. The alternative hypothesis to 
be proven is that the pathogen-inactivated platelets perform similar to control platelets within 
a pre-specified margin with regard to the primary endpoint. Based on discussions with 
clinicians as well as another large study using bleeding as an endpoint we decided that a 12.5 
percentage point increase as the upper limit of the 95% confidence interval of the absolute 
difference in grade ≥ 2 bleeding between the treatment arms was an acceptable margin, 
acknowledging improved safety with regard to the transmission of pathogens.17 To assess the 
non-inferiority hypothesis with a power of 80%, as well as adjustment (alpha and beta-
spending) for predefined interim analyses required a sample size of 578 (289 per arm). For 
safety reasons, frequent interim analyses were performed after every 60 patient transfusion 
treatment period randomized using a flexible stopping rule based on alpha and beta spending 
functions, allowing stopping for non-inferiority or futility.20 Before unblinding and starting 
the final analyses, a statistical analysis plan was written and agreed upon by the steering 
committee. The analysis of the primary endpoint as well as the majority of secondary 
endpoints were performed using three approaches: intention-to-treat (ITT), the per-protocol 
population (PP) and the per-protocol-only population (PPO) (Table S1 in the supplementary 
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appendix). The primary effect parameter was estimated according to a generalized estimating 
equation (GEE) approach using a generalized linear model with identity link and 
independence working correlation. The dependent variable was the yes/no indicator of having 
at least one ≥ grade 2 bleed during a transfusion treatment period. Covariates in the model 
were the treatment arm, the treatment period number (dichotomized as first or later) and the 
interaction between these two covariates. The 1-hour and 24-hour corrected count increments 
were analyzed using a linear mixed model using a random intercept per patient and a random 
intercept per treatment period to take into account the correlations between transfusions 
within treatment periods as well as between treatment periods within patients. Covariates 
were treatment arm, the number of the transfusion within the treatment period, the interaction 
between both and the pre-transfusion count. The platelet transfusion interval was analyzed 
with a mixed Poisson model with the number of transfusions per treatment period as 
dependent variable, the treatment arm as covariate, the log of the duration of the treatment 
period as an offset parameter and a random intercept per patient. The other numerical 
secondary outcomes that were measured only once per treatment period were compared based 
on the mean value per group with a similar GEE approach as for the primary outcome only 
now using a general linear model. For the analysis of the alloimmunization data, for patients 
with multiple randomizations, only results of the first randomizations were used. Patients 
were considered to be alloimmunized if at least one sample during 56 days after 
randomization had a signal higher than 5 standard deviations above the normalized 
background signal. We calculated Kaplan Meier curves for time-to-alloimmunization and 
compared both groups using a risk ratio for cumulative event probabilities estimated at 60 
days. All statistical analyses were performed using IBM SPSS Statistics (version 23). 
 
Study oversight 
Safety aspects of the study were closely watched by a Data Safety Monitoring Board 
(DSMB). Interim analyses after every 60 randomized patients were evaluated by the DSMB. 
The study was monitored for quality and regulatory compliance. The monitoring frequency 
depended on inclusion rates and findings from earlier visits. The authors vouch for the 
integrity of the data and analyses reported. The study was sponsored by Sanquin Blood 
Supply and registered at the Netherlands National Trial Registry under number NTR2106, and 
also at clinicaltrials.gov under number NCT02783313.  
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RESULTS 
From November 2010 until April 2016, randomization of 567 transfusion treatment periods 
took place in 469 patients. In November 2015, after analyzing 433 treatment periods the 
DSMB advised to stop recruiting patients, as analysis of the intention-to-treat population 
permitted a conclusion of non-inferiority for the primary endpoint. In close collaboration with 
the ethics review board, since there were no safety issues involved, the steering committee 
decided to continue patient accrual in order to reach the originally planned power of the study 
for the secondary endpoints, especially alloimmunization. Of the randomized transfusion 
treatment periods, 11 were excluded from further analyses as the patient had an active grade ≥ 
2 bleeding (N = 8) at randomization, or there was a gross lack of study compliance (N = 3, 
Figure 1). The intention-to-treat analyses were thus performed on 556 transfusion treatment 
periods. For the per-protocol analyses the data set consisted of 425 treatment periods after 
excluding patients who actively bled on the day of the first transfusion or did not receive any 
transfusion or received > 25% off-protocol transfusions (Figure 1). Randomization 
successfully balanced the most important risk factors for bleeding (Table 1).  
 
Bleeding 
In the intention-to-treat analysis, in 51% of the transfusion-treatment periods in the control 
arm the patient experienced a grade ≥2 WHO bleeding versus 54% in the intervention arm. 
The upper boundary of the 95% confidence interval of the difference between these two 
percentages did not exceed 12.5 percentage points, hence meeting the non-inferiority criterion 
(Table 2).  However, for the per-protocol analysis, 44% of patients receiving standard platelet 
products had a grade ≥2 bleeding, versus 52% in the intervention arm (Table 2).  The upper 
limit of the 95% confidence interval of this difference exceeded the prespecified limit, so the 
non-inferiority criterion was not met here (Figure 2). When looking at the percentage of 
bleeding days, there was no significant difference between the arms, irrespective of the 
analysis used. Also, when considering the highest bleeding grade, we saw no differences 
between the control and intervention arm. A further sub-analysis was performed for patients 
receiving only on-protocol transfusions, which showed similar outcome as compared to the 
per-protocol analysis (Table S2 in the supplementary appendix).  
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Transfusions 
Most platelet transfusions were given prophylactically (Table S3 and S4 in the supplementary 
appendix).  The pre-transfusion platelet count was about 15 x 109/L with no differences 
between the two arms. The platelet content in the products was about equal.13, 14 (Table S3 
and S4 in the supplementary appendix). Storage time was comparable, with 16 to 19% of the 
concentrates being stored for 6 or 7 days. The percentage of off-protocol transfusions in the 
intervention arm was 19.5% as compared to 11.6% in the control arm (p = 0.02). Off-protocol 
transfusions were denoted as “other”, and could consist of -for example- hyperconcentrated 
platelet products; platelets in additive solution in the control arm, and untreated platelets in 
the intervention arm. All transfusion increment parameters were significantly lower for 
pathogen-inactivated platelet concentrates versus untreated platelets. In the intervention arm, 
the count increments and corrected count increments were about 50% lower than the values in 
the control platelets arm, resulting in frequent transfusion “failures” (Table 3), a higher 
number of platelet transfusions and a shorter platelet transfusion interval (Table 4). There 
were no differences in the number of red cell- and plasma-units transfused in either arm, for 
both intention-to-treat and per-protocol analysis (Table 4).  
 
Safety: infections, (severe) adverse events, including transfusion reactions 
There were a considerable number of infectious complications, adverse events (AEs) and 
serious adverse events (SAEs), without differences between both study arms (Table S5 in the 
supplementary appendix). In both arms, one SAE was related to the platelet transfusion, an 
anaphylactic transfusion reaction to an off-protocol transfusion of platelets in additive 
solution in the control arm, and a transfusion-associated lung injury in the intervention arm 
(imputability possible). The percentage of transfusion reactions with imputability probable, 
possible, or certain was 2.8% in the control arm and 3.3% in the intervention arm. The 
majority of the transfusion reactions in both arms resulted in no or only minor morbidity.  
 
Alloimmunization 
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For the alloimmunization, we only included the first randomization transfusion treatment 
periods of patients (n=463). Excluding treatment periods with no or only one collected 
sample, as well as patients with HLA antibodies at the onset of their transfusion treatment 
period, resulted in 356 evaluable treatment periods in the per-protocol-only population 
(Control n = 177, Intervention n = 179). As shown in Figure 2, the number of patients 
developing HLA class I alloantibodies was similar: 6 in the control arm, as compared to 7 in 
the intervention arm (Risk ratio 1.00; 95% CI 0.34 – 2.98, p = 1.00). The intention-to-treat 
and per-protocol analyses are shown as supplemental material (Figures S2 and S3).  
 
DISCUSSION 
Using WHO bleeding as a primary outcome, we compared pathogen-inactivated platelet 
products using riboflavin and ultraviolet light, with standard plasma-stored platelet products 
in a multicenter, international randomized controlled trial using a non-inferiority design. The 
percentages of bleeding patients is in the same order of magnitude as other large randomized 
platelet transfusion trials, though somewhat higher as compared to the other two trials testing 
riboflavin/ ultraviolet  light treated platelets, indicating that bleeding symptoms were 
accurately captured in the participating sites.10,11, 17, 18 Although in the intention-to-treat 
analysis the  non-inferiority criterion was met,  the per-protocol analysis showed a slight 
increase in grade ≥ 2 bleeding complications in the intervention arm, and the upper limit of 
the 95% confidence interval of the difference crossed the margin of 12.5 percentage points. 
As has been recently discussed by Mauri and D’Agostino, in non-inferiority trials both the 
intention-to-treat as well as the per protocol analysis have important merits as well as pitfalls. 
Reporting both is considered to be the standard with similar results in both supporting the 
robustness of the findings.21  In our study in the intention-to-treat analysis, both off-protocol 
transfusions as well as the inclusion of bleeding complications occurring between 
randomization and the first on study platelet transfusion likely resulted in a diluting effect to 
the advantage of the intervention arm. However, the per-protocol analysis might be hampered 
by selection bias. It is conceivable that excluding patients with active bleedings at the day of 
the first on-study transfusion resulted in a bias to the advantage of the control arm by 
removing patients with a bleeding tendency.  A modified PP analysis, not excluding patients 
with active bleeding, reduced the difference with regard to bleeding complications between 
both populations slightly, though still not meeting the non-inferiority criterion.  
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With regard to secondary bleeding endpoints, there were no differences between both study 
arms. Importantly, though the numbers are small, no differences were observed in severe 
bleeding complications, pertinent to daily clinical practice. There were no differences with 
regard to the consumption of red cell concentrates or plasma, considered to be surrogate 
markers for clinically significant bleeding complications.   
The small detrimental effect on hemostasis seen in de per protocol analysis is in concordance 
with the conclusions of the most recent Cochrane analysis on pathogen reduction as well as 
the outcome of the recently published EFFIPAP study, which compared amotosalen- 
ultraviolet A treated platelets with platelets in plasma as well as platelet additive solution.8, 22 
The observed increase in bleeding complications is likely due to the detrimental effects on 
platelet function induced by pathogen reduction as has been shown in vitro for all the 
currently available pathogen reduction techniques.23,24   
All transfusion increment parameters were in favor of the control arm, which translated to a 
higher usage of platelet products in the intervention arm because the transfusion trigger is met 
sooner, with an increase of approximately 1 product per patient. This is as expected, recently 
published clinical studies comparing pathogen reduced platelet concentrates with untreated 
platelets also report higher platelet transfusion need.11, 22  Possibly, the lower corrected count 
increments are also due to the effects on platelets induced by pathogen inactivation, described 
for several pathogen inactivation methods .22, 25,26  This subject should be the basis for future 
research.  
As expected in this population, there was a high number of adverse and serious adverse 
events, with only two serious adverse events related to a platelet transfusion. In the 
intervention arm a possible transfusion related acute long injury (TRALI) was reported. All 
platelet products in plasma can cause a TRALI, and since pathogen inactivation does not 
target proteins, such an occurrence is not unexpected.  In contrast to recently published animal 
studies, pathogen inactivation treatment did not result in a reduction of HLA class I 
alloimmunization.7, 27 As the percentage of immunized patients is low in both arms, this result 
may be completely explained by randomness. Additionally, the discrepancy between animal 
and human studies may be explained by the administration of untreated red blood cells in 
patients in both arms, which did not occur in the animal experiments. The recently published 
data of the IPTAS trial also reported comparable low rates of HLA class I antibodies.28 
Numbers of countries, hospitals, patients, the large number of platelet transfusions and the 
large number of observed days are the main strengths of this study, contributing to the 
generalizability of conclusions regarding the clinical efficacy of pathogen-inactivated buffy-
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coat platelets in thrombocytopenic hematology patients. Despite efforts to reduce this, the 
main weakness of our study is the significant number of patients with off-protocol 
transfusions. Since our study has shown a mildly reduced hemostatic efficacy as well as a 
significant impact on transfusion increments, to implement or not to implement pathogen-
inactivated platelet products really depends on the balance of increased safety for known and 
unknown pathogens, which varies between countries worldwide, and the clinical effects that 
pathogen inactivation causes to the platelet product. Health-economic arguments should also 
be taken into account. Clearly there is room and need to improve the current techniques of 
platelet pathogen inactivation. Indeed replacing plasma by novel additive solutions has 
recently shown promising results.29 Moreover a clinical trial using pathogen inactivation in 
apheresis platelets, potentially contributing to a decreased risk in alloimmunization, is about 
to start.   
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Table 1 Patient characteristics  
 
  
    
  Control Intervention 
  n = 279 n = 277 
    
Male/female n / n 191 / 88 188 / 89 
Age Years, mean ± SD 54 ± 12 54 ± 12 
Body surface area m2, mean ± SD 1.97 ± 0.25 2.00 ± 0.24 
Enlarged spleen n (%) 17 (6.1)† 31 (11) 
Multiple inclusions n (%) 57 (20) 39 (14) 
Diagnosis    
  Acute myeloid leukemia n (%) 132 (47) 133 (48) 
  Acute lymphoblastic leukemia n (%) 25(9.0) 24 (8.6) 
  Mantle cell lymphoma n (%) 13 (4.7) 14 (5.0) 
  Non-Hodgkin’s lymphoma n (%) 41 (15) 38 (14) 
  Multiple myeloma n (%) 43 (15) 45 (16) 
  Chronic leukemia n (%) 3 (1.1) - 
  Other n (%) 22 (7.9) 23 (8.3) 
Treatment    
  Remission induction chemotherapy n (%) 119 (43) 116 (42) 
  Consolidation chemotherapy n (%) 32 (12) 35 (13) 
  Autologous stem cell transplantation n (%) 101 (36) 103 (37) 
  Allogenic stem cell transplantation n (%) 25 (9.0) 16 (5.8) 
  Other n (%) 2(0.7) 7 (2.5) 
Laboratory values at randomization    
  Platelet count 109/L, mean ± SD 87 ± 100 79 ± 75 
  Hemoglobin g/L, mean ± SD 81 ± 29 82 ± 24 
  Activated partial thromboplastin time s, mean ± SD 29 ± 7.9 29 ± 8.7 
  Prothrombin time s, mean ± SD 12 ± 2.2 12 ± 1.9 
  Fibrinogen g/L, mean ± SD 3.7 ± 1.3 3.6 ± 1.4 
Medication and medical history    
  Anticoagulant/antiplatelet therapy n (%) 30 (11) 31 (11) 
  Bleeding n (%) 67 (24) 72 (26) 
  Infection n (%) 26 (9.3) 27 (10) 
  Prior platelet transfusions n (%) 181 (67) 162 (60) 
  Prior red cell transfusions n (%) 197 (71) 191 (69) 
  Prior stem cell transplant procedures n (%) 22 (7.9)† 9 (3.2) 
  Prior pregnancies n (%) 61 (22) 66 (24) 
n = number of transfusion treatment periods; SD = Standard deviation; †p < 0.05 
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Table 2  
Bleeding complications (intention to treat analysis) 
  Control Intervention  
No. of transfusion treatment periods  279 277  
Primary endpoint     
WHO grade 2, 3 or 4 bleeding#  143 (51%) 150 (54%)  
No. of days from randomization to first grade 2, 3, or 4 bleeding median (IQR) 5 (2-8)  5.5 (2-9)  
     
Percentage of days with grade 2, 3, or 4 bleeding$  median (IQR) 3 (0-14) 5 (0-15)  
 No. of days with grade 2, 3, or 4 bleeding median (IQR) 1 (0-2) 1 (0-2)  
Bleeding details     
Highest grade of bleeding     
  None or grade 1  136 (49%) 127 (46%)  
  Grade 2  131 (47%) 139 (50%)  
  Grade 3  6 (2%) 5 (2%)  
  Grade 4  6 (2%) 6 (2%)  
WHO = world health organization; IQR=interquartile range 
# difference: 3 percentage points, 95% CI (-6 to 11), p-value for non-inferiority 0.012 
  after correcting for stratification factors (center, diagnosis AML/non-AML and treatment phase conventional/stem cell):  
  difference: 1 percentage points, 95% CI (-6 to 9), p-value for non-inferiority 0.002  
$ p-value for superiority of mean percentages 0.535 
 
 
Bleeding complications (per protocol analysis) 
  Control Intervention  
No. of transfusion treatment periods  220 205  
Primary endpoint     
WHO grade 2, 3 or 4 bleeding#  97 (44%) 107 (52%)  
No. of days from first transfusion to first grade 2, 3, or 4 bleeding median (IQR) 3 (1-5) 3 (1-5)  
     
Percentage of days with grade 2, 3, or 4 bleeding$ median (IQR)  0 (0-15) 4 (0-17)  
 No. of days with grade 2, 3, or 4 bleeding median (IQR) 0 (0-2) 1 (0-2)  
Bleeding details     
Highest grade of bleeding     
  None or grade 1  123 (56%) 98 (48%)  
  Grade 2  87 (40%) 102 (50%)  
  Grade 3  4 (2%) 2 (1%)  
  Grade 4  6 (3%) 3 (2%)  
WHO = world health organization; IQR=interquartile range 
# difference:8 percentage points, 95% CI (-2 to 18), p-value for non-inferiority 0.19  
  after correcting for stratification factors (center, diagnosis AML/non-AML and treatment phase conventional/stem cell):  
  difference: 10 percentage points, 95% CI (1 to 19), p-value for non-inferiority 0.29  
$ p-value for superiority of mean percentages 0.538 
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Table 3  
Platelet transfusion increment (intention to treat)     
  Control Intervention  
No. of platelet transfusions  1568 1659  
     
Efficacy parameters     
CI-1 hour 109/L mean ± SD  25 ± 14 (n=848) 13 ± 8 (n=997)  
CCI-1 hour mean ± SD 13 ± 7 (n=848) 8 ± 5  (n=997) p-value<0.001 
CI-24 hour 109/L mean ± SD  14 ± 14 (n=953) 8 ± 9 (n=1007)  
CCI-24 hour mean ± SD 7 ± 7  (n=953) 4 ± 4 (n=1007) p-value<0.001 
Transfusion failure     
CCI-1 hour < 7.5 failure rate    median (IQR) 0 (0-0.08)  0.5 (0.09-0.75) p-value<0.001 
CCI-24 hour < 4.5 failure rate    median (IQR) 0 (0-0.33) 0.50 (0.20-0.83) p-value<0.001 
CCI-24 hour ≤ 0 failure rate    median (IQR) 0 (0-0) 0 (0-0.08) p value=0.013 
CI = Count increment; CCI = Corrected count increment; SD = Standard deviation  
 
 
Platelet transfusion increment (per protocol) 
  Control  Intervention  
No. of platelet transfusions  1395 1391  
 
Efficacy parameters 
    
CI-1 hour mean ± SD 109/L 25 ± 14 (n=796) 12 ± 8 (n=868)  
CCI-1 hour mean ± SD 13 ± 7 (n=796) 7 ± 4  (n=868) p-value<0.001 
CI-24 hour mean ± SD 109/L 14 ± 14 (n=895) 7 ± 8  (n=897)  
CCI-24 hour mean ± SD 8 ± 7  (n=895) 4 ± 4  (n=897) p-value<0.001 
Transfusion failure     
CCI-1 hour < 7.5 failure rate    median (IQR) 0 (0-0.02)  0.50 (0.16-0.89) p-value<0.001 
CCI-24 hour < 4.5 failure rate    median (IQR) 0 (0-0.33) 0.50 (0.18-0.93) p-value<0.001 
CCI-24 hour ≤ 0 failure rate    median (IQR) 0 (0-0) 0 (0-0.02) p value=0.014 
CI = Count increment; CCI = Corrected count increment; SD = Standard deviation  
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Table 4.  
Transfusion requirement (intention to treat). 
  Control Intervention  
No. of transfusion treatment periods  279  277   
     
No. of red cell transfusions  median (IQR) 4 (2-7) 4 (2-6) p-value=0.135 
No. of plasma transfusions median (IQR) 0 (0-0) 0 (0-0) p-value=0.842 
PLT transfusion interval1  mean hours (95% CI)  83 (77-91)  71 (67-77) p-value=0.002 
No. of PLT transfusions per transfusion 
treatment period 
median (IQR) 4 (2-7) 5 (2.5-7.5) p value=0.328 
IQR = Interquartile range; PLT = Platelet; SD = Standard deviation; 1using all treatment periods via mixed Poisson model 
 
Transfusion requirement (per protocol). 
  Control Intervention  
No. of transfusion treatment periods  220  205   
     
No. of red cell transfusions  median (IQR) 3 (2-6) 3 (2-5) p-value=0.34 
No. of plasma transfusions  median (IQR) 0 (0-0) 0 (0-0) p-value=0.59 
PLT transfusion interval1  mean hours (95% CI)  91 (83-100)  71 (67-77) p-value<0.001 
No. of PLT transfusions per transfusion 
treatment period  
median (IQR) 3 (2-6.75) 5 (3-7.5) p-value=0.085 
 IQR = Interquartile range; PLT = Platelet; SD = Standard deviation; 1using all treatment periods via mixed Poisson model) 
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Figure legends 
Figure 1. Flow diagram of the study. In total, 567 randomizations occurred in 469 patients. 
The intention-to-treat analysis set consisted of all transfusion treatment periods in which the 
patient met the in- and exclusion criteria. In the event of >25% off-protocol transfusions or no 
transfusions, these episodes were analyzed ‘as randomized’. For the intention-to-treat  
analysis, the first day of observation was the day of randomization. The per-protocol set 
consisted of all ‘on-protocol’ episodes, i.e. episodes in which the percentage of off-protocol 
transfusions exceeded 25% before the first ≥ grade 2 bleeding event or episodes without 
transfusions were excluded. For the per-protocol analysis, the first day of observation was the 
day of the first platelet transfusion. The per-protocol-only analysis set consisted of all 
transfusion treatment periods in which only on-protocol transfusions are administered before a 
grade ≥2 bleeding occurred; the first day of observation was the day of the first platelet 
transfusion. 
 
Figuur 2. Non inferiority plot comparing the difference in percentage of transfusion 
treatment periods with world health organization grade 2,3,4 bleeding in the 
intervention – and control –arm. The point estimates of the difference in percentage points 
and their 95% confidence intervals are displayed for the intention- to- treat analysis and the 
per –protocol analysis. The dotted vertical line shows the predefined margin of 12.5 
percentage points. For the intention –to-treat analysis the non- inferiority criterion is met. For 
the per-protocol analysis the 95% confidence interval exceeds the margin of 12.5% points, the 
non- inferiority criterion is not satisfied.   
 
Figure 3. Kaplan - Meier analysis HLA-class I alloimmunization.  This figure shows the 
time to the appearance of HLA-class I alloantibodies in the PPO population (i.e. a signal 
higher than 5SD above the normalized background signal in the Luminex assay). 
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Figure 1. Flow diagram of the study.  
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Figuur 2. Non inferiority plot comparing the difference in percentage of transfusion treatment 
periods with world health organization grade 2,3,4 bleeding in the intervention – and control –
arm.  
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Figure 3.  Kaplan-Meier analysis HLA alloimmunization.  
 
 
 
 
 
